Dose Escalation Study of MLN4924 in Adults With Melanoma
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the
safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2
dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.